6 items found in 1 pages
The OPTIC study: Patient views on optimising immunotherapy in cancer
Optimisation immunotherapy clinical trials investigate ways of reducing the intensity of immunotherapy cancer treatment. This could be beneficial for patients’ quality of life. But these trials can be challenging to run, as patients may be concerned about the impact that reducing the intensity of treatment could have on the cancer. This episode of the Trial Talk podcast focuses on the MRC Clinical Trials Unit at UCL’s OPTIC study, which explores how people with cancer feel about taking part in optimisation immunotherapy trials. Clinical Fellow Sophie Merrick discusses the main barriers that patients face and recommendations to address them. Resources: •OPTIC study page: www.mrcctu.ucl.ac.uk/studies/all-st…/refine/optic/ •OPTIC results paper: www.nature.com/articles/s41416-024-02756-x.pdf •REFINE podcast episode: on.soundcloud.com/Fe3C76csHkgCg2or5 For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: bit.ly
0
6/18/2024
The REFINE trial: how can we improve the way we give cancer immunotherapy?
Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer. However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side effects. In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs. Further information is available on the REFINE study page at www.mrcctu.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: https://bit.ly/3DgIDE2
0
7/18/2023
Yin Wu - Cancer immunology: putting the pedal to the metal
Yin Wu, Clinical Lecturer TCT Lab, UCL Cancer Institute Rethinking Cancer | UCL Cancer Domain Symposium Monday 13 May 2019 Early Careers Network Session Cancer remains one of the major causes of morbidity and premature death worldwide; one in two people in the UK born after 1960 will be diagnosed with some form of cancer during their lifetime. UCL has a proud track record in addressing the societal, technical, and health challenges of cancer and in exploring its underling biology. This symposium, invited our broad community to assemble for the first time at scale to consider challenges and opportunities in cancer research, prevention and treatment, from biological, clinical, technical, economic and societal perspectives.
892
6/6/2019
Dr Claire Roddie - Cellular Immunotherapy for Cancer: better targets, better targeting
Dr Claire Roddie Consultant Haematologist; Honorary Senior Lecturer in Haematology, UCL Rethinking Cancer | UCL Cancer Domain Symposium Monday 13 May 2019 The cancer treatment revolution and how we afford it? Cancer remains one of the major causes of morbidity and premature death worldwide; one in two people in the UK born after 1960 will be diagnosed with some form of cancer during their lifetime. UCL has a proud track record in addressing the societal, technical, and health challenges of cancer and in exploring its underling biology. This symposium, invited our broad community to assemble for the first time at scale to consider challenges and opportunities in cancer research, prevention and treatment, from biological, clinical, technical, economic and societal perspectives.
853
6/4/2019
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
The immune system is constantly on the lookout for diseased cells. Every cell in our body has signals on their surface that reach out to immune cells, letting them know if everything is ok, or if the cell is unhealthy. Signals from diseased cells will cause the immune system to attack and kill those faulty cells. But in many lung cancers, the cancer cells lose about half of those signals to the immune system. This lets the cancer cells hide from the immune attacks, and allows the cancer to keep growing. Researchers have developed a computational toolset to help investigate how many of these signals to the immune cells are left on a cancer cell, based on DNA sequencing information. Hopefully this will help us develop more focused immune therapy in the future. First author: Rachel Rosenthal Corresponding authors: Professor Charles Swanton and Dr Nicholas McGranahan Research paper: http://www.cell.com/cell/fulltext/S0092-8674(17)31185-6
12578
11/3/2017
MSc Cancer at UCL - Christian Pellegrino
Led by by research scientists and academic clinicians, the MSc Cancer programme reflects the depth and breadth of research expertise within UCL Cancer Institute. Christian Pellegrino talks about his experience studying MSc Cancer at UCL. Find out more at www.ucl.ac.uk/cancer/study
24790
7/5/2016